Feishuiliuwairentian cbmg acquires car-t immunotherapy of PLA General Hospital

On February 9, cbmg announced the acquisition of car-t cell therapy of PLA General Hospital (301 Hospital) The acquisition includes CD19, CD20, CD30, recombinant expression vector of human epidermal growth factor receptor (EGFR), existing clinical I / II results, ownership of related patents, and production technology However, it did not disclose the key financial details of the acquisition, including the down payment, milestone payment, and sales dividend Chimeric antigen receptor T cell (car-t) therapy is one of the most promising immunotherapies In car-t cell therapy, the fusion protein of scFv and T cell activation sequence, which can recognize tumor associated antigen, is expressed on the surface of T cell through foreign gene transfection technology In this way, scFv is coupled with the signal domain of activation and proliferation in T cell through transmembrane region, and then expanded on a large scale after being transported back to the patient's body, so as to show strong anti-cancer effect Some early clinical experiments show that car-t cell therapy is very effective for blood tumors, and it is a subversive breakthrough in cancer research Car-t cell therapy may be one of the most likely treatments for cancer Because of the wide application prospects of car-t cell therapy, including the United States, the United Kingdom, Sweden, China, Japan and other countries around the world are actively carrying out clinical development related to car-t therapy The most cutting-edge research institutions of car-t therapy are the University of Pennsylvania, the American Cancer Institute (NCI), the Fred Hutchinson Cancer Research Center, the memorial Sloan Kettering Cancer center, Seattle Children's Hospital, etc In addition to Novartis and the University of Pennsylvania to develop car-t therapy, pharmaceutical giants such as celgene, GlaxoSmithKline and Pfizer have joined the ranks of car-t cell therapy In 2014, Hutchinson, Sloan Kettering and scientists from Seattle Children's Hospital jointly established Juno therapeutics, a biopharmaceutical company focusing on the development of car-t and TCT cell therapy, which raised more than 300 million US dollars twice a year, becoming the most funded start-up biopharmaceutical company in history Other main competitors of car-t cell therapy include kit biopharmaceutical company, Bluebird bio, cellectis, etc In short, car-t technology is the darling of the pharmaceutical industry at present, a "car" in the hands of money China started later in the field of car-t therapy, and is still in the name of "the third type of medical technology", and the technology adopted has not been reported in detail In front of us are Peking University Cancer Hospital and PLA General Hospital (301 Hospital) According to the information disclosed in the above news, the acquisition should be the technology of Professor Han Weidong, the Immunology Department of the General Hospital of the PLA Although there is no uniform technical standard for car-t cell therapy, they are different in car design, culture technology, lymphocyte removal methods and so on For example, NCI uses a second-generation car technology targeting CD19 containing CD28 costimulatory domain, which uses retrovirus for gene transduction, OKT3 and IL2 amplification to treat non Hodgkin's lymphoma Although no systematic report has been seen, according to some Internet information, some blood cancer patients get partial or even complete remission through car-t treatment in PLA General Hospital So Han Weidong's car-t cell therapy must have its own unique technology Moreover, it is said that Professor Han's research team has studied the construction of car-t targeting CD19 positive all patients, CD20 positive lymphoma, CD30 positive Hodgkin's lymphoma and EGFR positive advanced lung cancer Today, car-t technology is obviously a "big pie", it is a little puzzling that China's leading car-t technology is transferred to an unknown emerging biopharmaceutical company If it is a "golden egg", I believe that China has enough insight and should not let it "depreciate" to the other side of the Atlantic Ocean Cell biomedicine group, Inc develops proprietary cell therapies for some degenerative diseases and cancers The company's development stem cells, progenitor cells and immune cells are the research and development results of scientists and doctors in China and the United States The company's flagship GMP certified factory consists of eight independent cell production lines, which are designed, certified and managed in accordance with relevant American standards.